During the month of October, the number of shares and votes in SynAct Pharma AB have increased due to the directed issue of shares which was resolved upon by the board of directors on 11 October 2023.
As of 31 October 2023, the total number of shares and votes in SynAct Pharma AB amounts to 35,570,980.
For further information, please contact:
Torbjørn Bjerke, MD
CEO, SynAct Pharma AB
Phone: +46 727 44 41 58
Mail: [email protected]
Mail: [email protected]
About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.